Phase 4 Trial Involving Teduglutide Patients Marked Completed

A clinical trial relevant to teduglutide was updated on October 15, 2026. The study, titled "Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition," is registered as NCT04344717. It is listed as a Phase 4 trial. Its current status is marked as completed. The trial examines short bowel syndrome patients who require long term parenteral nutrition, a population in which teduglutide is used. No results or outcome data were provided in this update. The update reflects only the trial's status change to completed as of the stated date. For details on trial design, enrollment criteria, or further documentation, readers can consult the official registry listing. This brief does not include any efficacy or safety conclusions, as none were part of the reported update. Readers interested in teduglutide's approved use and general background can refer to the compound overview for additional context.